The anti-CTLA-4 antibody Ipilimumab, in combination with the anti-PD-1 antibody Nivolumab, has been FDA-approved for the treatment of melanoma, lung cancer, and renal cell carcinoma, among other cancers [41,42]. The gene discussed is CTLA4; the disease is melanoma.